BofA Cuts Nike to Underperform as Turnaround Takes Longer
BofA slashes Nike EPS estimates by 11% and 12% for FY27 and FY28 and now sits 14% below Visible Alpha consensus.
Already have an account? Sign in.
BofA slashes Nike EPS estimates by 11% and 12% for FY27 and FY28 and now sits 14% below Visible Alpha consensus.
Leerink cut Bristol Myers and raised Zentalis. Barclays lowered uniQure. Cantor upgraded Rezolute. New Buy calls on Ovid, Maravai, and Regenxbio.
Morgan Stanley keeps a bullish view on SpaceX, citing growth and a cheaper way into the space and intelligence economy ahead of Flight 15.
Option Care Health is in advanced talks on a joint bid from McKesson and CD&R valuing it at more than $5 billion, including debt.